<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36763102</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-7099</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Innere Medizin (Heidelberg, Germany)</Title><ISOAbbreviation>Inn Med (Heidelb)</ISOAbbreviation></Journal><ArticleTitle>[Lupus nephritis: from diagnosis to treatment].</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>233</EndPage><MedlinePgn>225-233</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00108-023-01489-y</ELocationID><Abstract><AbstractText>Renal involvement in systemic lupus erythematosus (SLE), so-called lupus nephritis (LN), is one of the most frequent organ manifestations with an incidence of approximately 40-60%. It is not uncommon for renal involvement to be the initial manifestation of SLE or to occur in the first 5-10&#xa0;years after diagnosis of SLE. Urinalysis is useful in screening for the presence of LN, demonstrating proteinuria or active sediment with acanthocytes. Histologic confirmation of LN, and thus the LN class present, is currently the gold standard for confirming the diagnosis. In addition, knowledge of the LN class is a&#xa0;relevant component of adequate treatment planning in SLE patients with LN. In particular, early diagnosis and rapid response to therapy are of prognostic importance for the preservation of renal function as well as morbidity and mortality of the mostly young patients at the time of initial diagnosis. Thus, the focus of therapy is to achieve complete remission, as well as to avoid active disease phases. Due to a&#xa0;complex pathogenesis and at the same time a&#xa0;very heterogeneous clinical presentation, with six different histological classes of LN, there are different therapeutic targets. This in turn results in a&#xa0;significant expansion of the study landscape in the field of LN with an increasing understanding of the signaling pathways and influencing factors, and fortunately in a&#xa0;growing armamentarium of available targeted therapy options. Simultaneously, new insights into drug therapy to inhibit progression of chronic renal disease are opening up supportive therapy options that can further improve preservation of renal function.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinmann-Menke</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>I.&#xa0;Medizinische Klinik und Poliklinik, Schwerpunkt Nephrologie und Nierentransplantation, Universit&#xe4;tsmedizin Mainz, Langenbeckstr.&#xa0;1, 55131, Mainz, Deutschland. julia.weinmann-menke@unimedizin-mainz.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Lupusnephritis&#xa0;&#x2013; von der Diagnose zur Therapie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Inn Med (Heidelb)</MedlineTA><NlmUniqueID>9918384885306676</NlmUniqueID><ISSNLinking>2731-7080</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Die Nierenbeteiligung bei systemischem Lupus erythematodes (SLE), die sogenannte Lupusnephritis (LN), ist mit einer Inzidenz von etwa 40 bis 60&#x202f;% eine der h&#xe4;ufigsten Organmanifestationen. Die Nierenbeteiligung stellt nicht selten die Erstmanifestation des SLE dar bzw. tritt in den ersten 5&#x2013;10&#xa0;Jahren nach Diagnosestellung eines SLE auf. Zum Screening auf das Vorliegen einer LN eignet sich die Urinanalyse, bei der eine Proteinurie oder ein aktives Sediment mit Akanthozyten nachweisbar wird. Die histologische Sicherung der LN und damit der vorliegenden LN-Klasse ist zurzeit der Goldstandard der Diagnosesicherung. Zudem ist das Wissen &#xfc;ber die LN-Klasse ein relevanter Bestandteil der ad&#xe4;quaten Therapieplanung bei Patienten mit SLE und LN. Hier sind insbesondere die fr&#xfc;he Diagnosestellung sowie das rasche Ansprechen auf die eingesetzten Therapien von prognostischer Bedeutung f&#xfc;r den Erhalt der Nierenfunktion sowie f&#xfc;r die Morbidit&#xe4;t und Mortalit&#xe4;t der zum Zeitpunkt der Erstdiagnose meist jungen Patienten. Im Mittelpunkt der Therapie stehen somit das Erreichen einer vollst&#xe4;ndigen Remission und das Vermeiden aktiver Krankheitsphasen. Aufgrund einer komplexen Pathogenese bei gleichzeitig sehr heterogenem klinischem Erscheinungsbild mit sechs verschiedenen histologischen Klassen der LN ergeben sich unterschiedliche Therapieangriffspunkte. Dies wiederum resultiert bei zunehmendem Verst&#xe4;ndnis der Signalwege und Einflussfaktoren in einer deutlichen Expansion der Studienlandschaft im Bereich der LN und erfreulicherweise in einem wachsenden Armamentarium an verf&#xfc;gbaren zielgerichteten Therapieoptionen. Zugleich er&#xf6;ffnen neue Erkenntnisse in der medikament&#xf6;sen Therapie zur Progressionshemmung der chronischen Niereninsuffizienz supportive Therapieoptionen, die den Erhalt der Nierenfunktion noch verbessern k&#xf6;nnen.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kidney biopsy</Keyword><Keyword MajorTopicYN="N">Lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">Lupus nephritis/classification</Keyword><Keyword MajorTopicYN="N">Molecular targeted therapy</Keyword><Keyword MajorTopicYN="N">Proteinuria</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36763102</ArticleId><ArticleId IdType="doi">10.1007/s00108-023-01489-y</ArticleId><ArticleId IdType="pii">10.1007/s00108-023-01489-y</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Anders&#xa0;HJ, Saxena&#xa0;R, Zhao&#xa0;MH, Parodis&#xa0;I, Salmon&#xa0;JE, Mohan&#xa0;C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">31974366</ArticleId><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson&#xa0;PC, Kashgarian&#xa0;M, Moeckel&#xa0;G (2018) Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney&#xa0;J 11(2):207&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pubmed">29644061</ArticleId><ArticleId IdType="doi">10.1093/ckj/sfx093</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand&#xa0;EF, Furie&#xa0;R, Tanaka&#xa0;Y, Bruce&#xa0;IN, Askanase&#xa0;AD, Richez&#xa0;C et&#xa0;al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N&#xa0;Engl J Med 382(3):211&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne&#xa0;D, Rovin&#xa0;B, Mysler&#xa0;EF, Furie&#xa0;RA, Houssiau&#xa0;FA, Trasieva&#xa0;T et&#xa0;al (2022) Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 81(4):496&#x2013;506</Citation><ArticleIdList><ArticleId IdType="pubmed">35144924</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarting&#xa0;A, Relle&#xa0;M, Meineck&#xa0;M, Fohr&#xa0;B, Triantafyllias&#xa0;K, Weinmann&#xa0;A et al (2018) Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus 27(2):243&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">28659046</ArticleId><ArticleId IdType="doi">10.1177/0961203317717083</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening&#xa0;JJ, D&#x2019;Agati&#xa0;VD, Schwartz&#xa0;MM, Seshan&#xa0;SV, Alpers&#xa0;CE, Appel&#xa0;GB et&#xa0;al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521&#x2013;530</Citation><ArticleIdList><ArticleId IdType="pubmed">14717922</ArticleId><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening&#xa0;JJ, D&#x2019;Agati&#xa0;VD, Schwartz&#xa0;MM, Seshan&#xa0;SV, Alpers&#xa0;CE, Appel&#xa0;GB et&#xa0;al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J&#xa0;Am Soc Nephrol 15(2):241&#x2013;250</Citation><ArticleIdList><ArticleId IdType="pubmed">14747370</ArticleId><ArticleId IdType="doi">10.1097/01.ASN.0000108969.21691.5D</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis&#xa0;A, Kostopoulou&#xa0;M, Cheema&#xa0;K, Anders&#xa0;HJ, Aringer&#xa0;M, Bajema&#xa0;I et al (2020) 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713&#x2013;723</Citation><ArticleIdList><ArticleId IdType="pubmed">32220834</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni&#xa0;G, Vercelloni&#xa0;PG, Quaglini&#xa0;S, Gatto&#xa0;M, Gianfreda&#xa0;D, Sacchi&#xa0;L et al (2018) Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a&#xa0;cohort of 499&#xa0;patients with lupus nephritis. Ann Rheum Dis 77(9):1318&#x2013;1325</Citation><ArticleIdList><ArticleId IdType="pubmed">29730634</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-212732</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar&#xa0;A, Alberton&#xa0;V, Lococo&#xa0;B, Ferrari&#xa0;M, Delgado&#xa0;P, Nagaraja&#xa0;HN et al (2020) Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 97(1):156&#x2013;162</Citation><ArticleIdList><ArticleId IdType="pubmed">31685314</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2019.07.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne&#xa0;D, Bajema&#xa0;IM (2020) &#x201c;In my beginning is my end&#x201d;: usefulness of repeat kidney biopsies in lupus nephritis. Kidney Int 97(1):27&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">31901351</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2019.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni&#xa0;G, Gatto&#xa0;M, Tamborini&#xa0;F, Quaglini&#xa0;S, Radice&#xa0;F, Saccon&#xa0;F et al (2020) Lack of EULAR/ERA-EDTA response at 1&#xa0;year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 79(8):1077&#x2013;1083</Citation><ArticleIdList><ArticleId IdType="pubmed">32503858</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216965</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis&#xa0;A, Tziolos&#xa0;N, Bertsias&#xa0;G, Boumpas&#xa0;DT (2021) Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80(1):14&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">33051219</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon&#xa0;GS, McGwin&#xa0;G, Bertoli&#xa0;AM, Fessler&#xa0;BJ, Calvo-Alen&#xa0;J, Bastian&#xa0;HM et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a&#xa0;multiethnic US cohort (LUMINA L). Ann Rheum Dis 66(9):1168&#x2013;1172</Citation><ArticleIdList><ArticleId IdType="pubmed">17389655</ArticleId><ArticleId IdType="pmc">1955128</ArticleId><ArticleId IdType="doi">10.1136/ard.2006.068676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel&#xa0;GJ, Alarcon&#xa0;GS, McGwin&#xa0;G Jr, Danila&#xa0;MI, Zhang&#xa0;J, Bastian&#xa0;HM et al (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a&#xa0;multiethnic US cohort. Arthritis Rheum 61(6):830&#x2013;839</Citation><ArticleIdList><ArticleId IdType="pubmed">19479701</ArticleId><ArticleId IdType="pmc">2898742</ArticleId><ArticleId IdType="doi">10.1002/art.24538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee&#xa0;SJ, Silverman&#xa0;E, Bargman&#xa0;JM (2011) The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 7(12):718&#x2013;729</Citation><ArticleIdList><ArticleId IdType="pubmed">22009248</ArticleId><ArticleId IdType="doi">10.1038/nrneph.2011.150</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi&#xa0;MY, Clarke&#xa0;AE, Urowitz&#xa0;M, Hanly&#xa0;J, St-Pierre&#xa0;Y, Gordon&#xa0;C et al (2022) Longitudinal analysis of ANA in the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 81(8):1143&#x2013;1150</Citation><ArticleIdList><ArticleId IdType="pubmed">35338033</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2022-222168</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow&#xa0;MK, Kirou&#xa0;KA (2022) Hydroxychloroquine and lupus flare: a&#xa0;good drug, but we need to do better. Ann Rheum Dis 81(3):303&#x2013;305</Citation><ArticleIdList><ArticleId IdType="pubmed">35039325</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221590</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmani&#xa0;Z, Schrama&#xa0;TJ, Zacouris-Verweij&#xa0;W, Andersen&#xa0;J, Frankel&#xa0;S, Bultink&#xa0;IEM et al (2021) Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. Lupus Sci Med 8(1):e478</Citation><ArticleIdList><ArticleId IdType="pubmed">33795484</ArticleId><ArticleId IdType="pmc">8021889</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler&#xa0;DC, Stefansson&#xa0;BV, Jongs&#xa0;N, Chertow&#xa0;GM, Greene&#xa0;T, Hou&#xa0;FF et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a&#xa0;prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(1):22&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">33338413</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(20)30369-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink&#xa0;HJL, Jongs&#xa0;N, Chertow&#xa0;GM, Langkilde&#xa0;AM, McMurray&#xa0;JJV, Correa-Rotter&#xa0;R et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a&#xa0;prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):743&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">34619108</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(21)00242-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris&#xa0;GL, Agarwal&#xa0;R, Anker&#xa0;SD, Pitt&#xa0;B, Ruilope&#xa0;LM, Rossing&#xa0;P et&#xa0;al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N&#xa0;Engl J Med 383(23):2219&#x2013;2229</Citation><ArticleIdList><ArticleId IdType="pubmed">33264825</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2025845</ArticleId></ArticleIdList></Reference><Reference><Citation>E&#x2011;KCG T, Herrington&#xa0;WG, Staplin&#xa0;N, Wanner&#xa0;C, Green&#xa0;JB, Hauske&#xa0;SJ et al (2023) Empagliflozin in patients with chronic kidney disease. N&#xa0;Engl J Med 388(2):117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler&#xa0;DC, Jongs&#xa0;N, Stefansson&#xa0;BV, Chertow&#xa0;GM, Greene&#xa0;T, Hou&#xa0;FF et al (2021) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab335</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab335</ArticleId><ArticleId IdType="pubmed">33094322</ArticleId><ArticleId IdType="pmc">9585467</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie&#xa0;R, Rovin&#xa0;BH, Houssiau&#xa0;F, Malvar&#xa0;A, Teng&#xa0;YKO, Contreras&#xa0;G et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N&#xa0;Engl J Med 383(12):1117&#x2013;1128</Citation><ArticleIdList><ArticleId IdType="pubmed">32937045</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax&#xa0;K, Mackay&#xa0;IR, Mackay&#xa0;F (2012) BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 64(7):595&#x2013;602</Citation><ArticleIdList><ArticleId IdType="pubmed">22641424</ArticleId><ArticleId IdType="doi">10.1002/iub.1046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin&#xa0;BH, Furie&#xa0;R, Teng&#xa0;YKO, Contreras&#xa0;G, Malvar&#xa0;A, Yu&#xa0;X et&#xa0;al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101(2):403&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pubmed">34560137</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan&#xa0;J, Moutzouris&#xa0;DA, Ginzler&#xa0;EM, Solomons&#xa0;N, Siempos&#xa0;II, Appel&#xa0;GB (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77(2):152&#x2013;160</Citation><ArticleIdList><ArticleId IdType="pubmed">19890271</ArticleId><ArticleId IdType="doi">10.1038/ki.2009.412</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen&#xa0;W, Tang&#xa0;X, Liu&#xa0;Q, Chen&#xa0;W, Fu&#xa0;P, Liu&#xa0;F et al (2011) Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 57(2):235&#x2013;244</Citation><ArticleIdList><ArticleId IdType="pubmed">21177013</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2010.08.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao&#xa0;R, Liu&#xa0;Q, Zheng&#xa0;Z, Fan&#xa0;J, Peng&#xa0;W, Kong&#xa0;Q et&#xa0;al (2015) Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS ONE 10(7):e132724</Citation><ArticleIdList><ArticleId IdType="pubmed">26161538</ArticleId><ArticleId IdType="pmc">4498640</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0132724</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau&#xa0;FA, Vasconcelos&#xa0;C, D&#x2019;Cruz&#xa0;D, Sebastiani&#xa0;GD, de Ramon Garrido&#xa0;E, Danieli&#xa0;MG et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69(1):61&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">19155235</ArticleId><ArticleId IdType="doi">10.1136/ard.2008.102533</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan&#xa0;TM, Li&#xa0;FK, Tang&#xa0;CS, Wong&#xa0;RW, Fang&#xa0;GX, Ji&#xa0;YL et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N&#xa0;Engl J Med 343(16):1156&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="pubmed">11036121</ArticleId><ArticleId IdType="doi">10.1056/NEJM200010193431604</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel&#xa0;GB, Contreras&#xa0;G, Dooley&#xa0;MA, Ginzler&#xa0;EM, Isenberg&#xa0;D, Jayne&#xa0;D et&#xa0;al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J&#xa0;Am Soc Nephrol 20(5):1103&#x2013;1112</Citation><ArticleIdList><ArticleId IdType="pubmed">19369404</ArticleId><ArticleId IdType="pmc">2678035</ArticleId><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler&#xa0;EM, Dooley&#xa0;MA, Aranow&#xa0;C, Kim&#xa0;MY, Buyon&#xa0;J, Merrill&#xa0;JT et&#xa0;al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N&#xa0;Engl J Med 353(21):2219&#x2013;2228</Citation><ArticleIdList><ArticleId IdType="pubmed">16306519</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa043731</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg&#xa0;D, Appel&#xa0;GB, Contreras&#xa0;G, Dooley&#xa0;MA, Ginzler&#xa0;EM, Jayne&#xa0;D et&#xa0;al (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49(1):128&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pubmed">19933596</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kep346</ArticleId></ArticleIdList></Reference><Reference><Citation>Park&#xa0;DJ, Kang&#xa0;JH, Lee&#xa0;KE, Bae&#xa0;SC, Chung&#xa0;WT, Choe&#xa0;JY et&#xa0;al (2019) Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a&#xa0;nationwide multicentre study. Clin Exp Rheumatol 37(1):89&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">29998829</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok&#xa0;CC, Ying&#xa0;KY, Yim&#xa0;CW, Siu&#xa0;YP, Tong&#xa0;KH, To&#xa0;CH et al (2016) Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a&#xa0;randomised controlled trial and long-term follow-up. Ann Rheum Dis 75(1):30&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">25550339</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206456</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau&#xa0;FA, D&#x2019;Cruz&#xa0;D, Sangle&#xa0;S, Remy&#xa0;P, Vasconcelos&#xa0;C, Petrovic&#xa0;R et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 69(12):2083&#x2013;2089</Citation><ArticleIdList><ArticleId IdType="pubmed">20833738</ArticleId><ArticleId IdType="doi">10.1136/ard.2010.131995</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley&#xa0;MA, Jayne&#xa0;D, Ginzler&#xa0;EM, Isenberg&#xa0;D, Olsen&#xa0;NJ, Wofsy&#xa0;D et&#xa0;al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N&#xa0;Engl J Med 365(20):1886&#x2013;1895</Citation><ArticleIdList><ArticleId IdType="pubmed">22087680</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1014460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou&#xa0;F, D&#x2019;Cruz&#xa0;D, Sangle&#xa0;S, Remy&#xa0;P, Vasconcelos&#xa0;C, Fiehn&#xa0;C et al (2016) Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75(3):526&#x2013;531</Citation><ArticleIdList><ArticleId IdType="pubmed">25757867</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin&#xa0;BH, Teng&#xa0;YKO, Ginzler&#xa0;EM, Arriens&#xa0;C, Caster&#xa0;DJ, Romero-Diaz&#xa0;J et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a&#xa0;double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397(10289):2070&#x2013;2080</Citation><ArticleIdList><ArticleId IdType="pubmed">33971155</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie&#xa0;RA, Aroca&#xa0;G, Cascino&#xa0;MD, Garg&#xa0;JP, Rovin&#xa0;BH, Alvarez&#xa0;A et al (2022) B&#x2011;cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a&#xa0;randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">34615636</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>